Regulatory: Food and Drug Safety Under the Obama Administration
Administration works to address potential weaknesses in food and drug safety.
July 20, 2010 at 08:00 PM
3 minute read
The original version of this story was published on Law.com
The Obama Administration has taken aggressive steps to address perceived weaknesses in the food and drug safety area. Many of these problems arose from the Food and Drug Administration's (FDA) slow response to the internationalization of supply chains.
Transforming Food Safety. FDA is developing a modern food import program to evaluate food safety programs in supplier countries and enhance its oversight and surveillance programs for imported foods. To help prevent foodborne illnesses, the agency will issue binding standards for inspection of produce and other food products and for analysis of samples. The FDA has also adopted a new process to assess the risks of imported foods as they enter the country and target shipments that pose the greatest risk for closer attention. Its priorities include imports of seafood and fresh produce and foods produced in China. These steps will allow the agency to better hold companies responsible for the performance of their global supply chains.
FDA is preparing new rules that will require menu disclosure of the calorie content and other nutritional information by chain restaurants and at vending machines. It also has played an important role in assuring the safety of seafood from the Gulf of Mexico after the Deepwater Horizon explosion.
Protecting Pharmaceutical Consumers. FDA is upgrading consumer protection programs intended to assure the safety of drugs, medical devices, vaccines (especially vaccines against flu viruses), and the nation's blood supply. This initiative also has a large international component, as 40 percent of the drugs and 80 percent of the active pharmaceutical ingredients for drugs consumed in the United States are from foreign sources. The agency now has three offices in China, three in Central America, and two in India that are intended to produce better quality controls at the point of production through cooperation with the home country regulator and more aggressive FDA surveillance and enforcement actions.
On the supervisory front, FDA has overseen a highly visible recall of Children's Tylenol for failure to comply with good manufacturing practices. The agency also is carefully reviewing unapproved drug claims that companies make on their websites and other forms of product advertising.
Improving Regulation of Medical Devices. In response to public criticism about the scientific and regulatory rigor of the medical device approval process, the FDA is adopting a more conservative and demanding regulatory approach that will make approval more difficult, costly, and time-consuming.
This multifront campaign to adapt the food and drug safety program to the era of globalization ultimately will require a larger budget and additional user fees by companies whose products are subject to FDA review.
John F. Cooney is a partner in the Washington, D.C., office of Venable.
Read John Cooney's previous column. Read John Cooney's next column.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllWhy Seemingly Simple Off-Channel Communication Rules Still Vex Finance Industry
5 minute readSEC Enforcement Chief Grewal—Whose Hard Line on Crypto Tormented the Industry—Stepping Down
4 minute readTrending Stories
Who Got The Work
Dechert partners Andrew J. Levander, Angela M. Liu and Neil A. Steiner have stepped in to defend Arbor Realty Trust and certain executives in a pending securities class action. The complaint, filed July 31 in New York Eastern District Court by Levi & Korsinsky, contends that the defendants concealed a 'toxic' mobile home portfolio, vastly overstated collateral in regards to the company's loans and failed to disclose an investigation of the company by the FBI. The case, assigned to U.S. District Judge Pamela K. Chen, is 1:24-cv-05347, Martin v. Arbor Realty Trust, Inc. et al.
Who Got The Work
Arthur G. Jakoby, Ryan Feeney and Maxim M.L. Nowak from Herrick Feinstein have stepped in to defend Charles Dilluvio and Seacor Capital in a pending securities lawsuit. The complaint, filed Sept. 30 in New York Southern District Court by the Securities and Exchange Commission, accuses the defendants of using consulting agreements, attorney opinion letters and other mechanisms to skirt regulations limiting stock sales by affiliate companies and allowing the defendants to unlawfully profit from sales of Enzolytics stock. The case, assigned to U.S. District Judge Andrew L. Carter Jr., is 1:24-cv-07362, Securities and Exchange Commission v. Zhabilov et al.
Who Got The Work
Clark Hill members Vincent Roskovensky and Kevin B. Watson have entered appearances for Architectural Steel and Associated Products in a pending environmental lawsuit. The complaint, filed Aug. 27 in Pennsylvania Eastern District Court by Brodsky & Smith on behalf of Hung Trinh, accuses the defendant of discharging polluted stormwater from its steel facility without a permit in violation of the Clean Water Act. The case, assigned to U.S. District Judge Gerald J. Pappert, is 2:24-cv-04490, Trinh v. Architectural Steel And Associated Products, Inc.
Who Got The Work
Michael R. Yellin of Cole Schotz has entered an appearance for S2 d/b/a the Shoe Surgeon, Dominic Chambrone a/k/a Dominic Ciambrone and other defendants in a pending trademark infringement lawsuit. The case, filed July 15 in New York Southern District Court by DLA Piper on behalf of Nike, seeks to enjoin Ciambrone and the other defendants in their attempts to build an 'entire multifaceted' retail empire through their unauthorized use of Nike’s trademark rights. The case, assigned to U.S. District Judge Naomi Reice Buchwald, is 1:24-cv-05307, Nike Inc. v. S2, Inc. et al.
Who Got The Work
Sullivan & Cromwell partner Adam S. Paris has entered an appearance for Orthofix Medical in a pending securities class action arising from a proposed acquisition of SeaSpine by Orthofix. The suit, filed Sept. 6 in California Southern District Court, by Girard Sharp and the Hall Firm, contends that the offering materials and related oral communications contained untrue statements of material fact. According to the complaint, the defendants made a series of misrepresentations about Orthofix’s disclosure controls and internal controls over financial reporting and ethical compliance. The case, assigned to U.S. District Judge Linda Lopez, is 3:24-cv-01593, O'Hara v. Orthofix Medical Inc. et al.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250